表皮生长因子受体18外显子E709_T710 delinsD突变肺癌一例报道  

EGFR Exon 18 E709_T710 delinsD Mutation of Lung Cancer:a Case Report

作　　者：郭昭君 毕经旺 GUO Zhaojun;BI Jingwang(Weifang Medical College,Weifang 261053,China;Department of Oncology,the 960th Hospital of the People's Liberation Army,Jinan 250031,China;Department of Oncology,Shandong Second People's Hospital,Jinan 250000,China)

机构地区：[1]潍坊医学院,山东省潍坊市261053 [2]中国人民解放军联勤保障部队第九六〇医院南院肿瘤科,山东省济南市250031 [3]山东省第二人民医院肿瘤科,山东省济南市250000

出　　处：《实用心脑肺血管病杂志》2023年第11期129-131,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：表皮生长因子受体(EGFR)基因突变常见于19外显子突变和21外显子突变,占所有肺癌患者的80%~90%,而18外显子突变少见。本文报道1例EGFR 18外显子E709_T710 delinsD突变的女性肺癌患者,其经化疗(培美曲塞+奈达铂+贝伐珠单抗)联合阿法替尼治疗后出现严重的腹泻及皮疹等毒副作用,之后将阿法替尼减量至隔日1次,患者耐受性良好,并顺利完成6周期化疗,院外坚持服用阿法替尼。化疗3个月后复查胸部CT显示病灶较前明显缩小,疗效评估为部分缓解。Epidermal growth factor receptor(EGFR)gene mutations are common in exon 19 mutations and exon 21 mutations,accounting for 80%-90%of all lung cancer patients,while exon 18 mutations are rare.This article reported a female lung cancer patient with EGFR exon 18 E709_T710 delinsD mutation.After the treatment with chemotherapy(pemetrexed+nedaplatin+bevacizumab)combined with afatinib,the patients developed severe side effects such as diarrhea and rash.After that,afatinib was reduced to once every other day,and the patient was well tolerated and successfully completed 6 cycles of chemotherapy,and insisted on taking afatinib outside the hospital.After 3 months of chemotherapy,chest CT showed that the lesion was significantly smaller than before,and the efficacy was evaluated as partial remission.

关 键 词：肺肿瘤 肺癌 表皮生长因子受体基因 18外显子突变 病例报告 

分 类 号：R734.2[医药卫生—肿瘤]